Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)

Inclusion Criteria:

• 30 years or older

• Able to provide written acknowledgement of giving informed consent

• Best corrected visual acuity (BCVA) 20/200 or better

• NTG in both eyes with untreated IOP <21 mmHg at Visit 2 and morning assessment ofVisit 3; IOP at morning assessment on Visits 2 and 3 doesn't differ more than 2mmHg; has open iridocorneal angles, historic IOP <22 mmHg in either eye

Exclusion Criteria:

• History of angle closure glaucoma, narrow or occludable angle on gonioscope

• All secondary glaucomas

• Severe glaucomatous damage that would preclude safe washout of prescribed ocularhypotensive medications

• Previous glaucoma surgery, certain procedures (trabeculotomy, shunt/tubes,cyclodestructive procedure) (selective laser trabeculoplasty (SLT) allowed if doneno earlier than 1 year from study, some minimally invasive glaucoma surgeries areallowed if done no earlier than 1.5 years from study)

• Ocular trauma, ocular infections, ocular inflammation, herpes simplex keratitis ofeye

• Use of other ophthalmic concomitant medications during the study

• Refractive surgery

• Uncontrolled hypertension or hypotension

• Significant systemic or psychiatric disease

• Participation in other investigational trial 30 days prior to screening or previousenrollment and treatment with Qlaris investigational product

• Pregnant or lactating